RegenPRP™ + ATS
The standardised leucocyte-reduced
platelet concentrate prepared with
RegenLab® technology that provides
an autologous reservoir of growth factors.
What is Plus Technology ?
What is RegenPRP™ ?
RegenPRP™: the platelet concentrate prepared with Regen Lab technology provides an autologous reservoir of growth factors.
Platelets, in addition to their role in hemostasis, are key factors in tissue repair mechanisms.1 They provide essential growth factors, such as FGF, PDGF, TGF-β, EGF, VEGF, IGF, which are involved in stem cells migration, differentiation and proliferation. Platelet growth factors also stimulate fibroblasts and endothelial cells to induce the deposition of new extracellular matrix and neovascularisation, respectively.
Plasma contains many factors essential for cell survival including nutrients, vitamins, hormones, electrolytes, growth factors (such as IGF and HGF), and proteins. Among the plasma proteins, the molecules vital for the coagulation process and for formation of the fibrin polymer will serve as a scaffold for cell migration and new tissue generation.2
Platelet-Rich Plasma
• Proven role in the healing of tissues, with key roles in cell migration, proliferation and differentiation
• Mechanism of action comprises anti-inflammatory activity and activation of cell-signalling cascades
• Key role in the synthesis of new extracellular matrix for tissue regeneration
What is ATS ?
ATS is an autologous serum used to activate RegenPRP™ coagulation via a physiological pathway.
This serum contains the enzymes of the coagulation cascade in their active form, among them thrombin. Thrombin is the enzyme that converts soluble plasma fibrinogen to fibrin monomers which polymerise to form the clot. Addition of ATS, either alone or with a calcium solution, to RegenPRP™ triggers the coagulation process in a physiological manner.
This natural process induces the formation of a three-dimensional fibrin matrix in which the platelets are entrapped. This allows a long-lasting growth factor delivery at the treatment site and the fibrin matrix serves as a scaffold for new tissue reconstruction.
PRP gel preparation
The addition of autologous thrombin serum (ATS) to the Regen PRP physiologically starts the coagulation process and thus enables the production of a leukocyte-reduced platelet gel.
Autologous Thrombin Serum (ATS) converts soluble fibrinogen into fibrin monomers, which polymerize into a clot.
This natural process induces the formation of a three-dimensional fibrin matrix in which the platelets are embedded. This enables long-lasting growth factor delivery at the treatment site and the matrix serves as a scaffold for new tissue reconstruction.
The coagulation process is a complex cascade of reactions that causes the thrombin to convert soluble fibrinogen into insoluble fibrin molecules that form the fibrin clot. If calcium is added, this accelerates the process and the fibrin structure is strengthened.
Technology advantages
————–
- User-independent standardised preparations
- Minimum volume of blood required
- Safe closed-circuit systems
- Mechanical separation of PRP and ATS using a chemically inert separator gel after a 5-minute centrifugation at 1500g
- Pharmaceutical grade solution of sodium citrate allowing a reversible anticoagulation
- Induction of PRP coagulation by addition of ATS, either alone or combined with a calcium solution
- Minimal learning curve and ease of use
- Operationally and clinically efficient process
- Facilitates and streamlines routine practice
Scientific advantages
————–
- Demonstrated safety and efficacy
- Evidence-based outcomes for numerous therapeutic indications
- Clinical studies, with over 200 publications
Biological advantages
————–
- RegenPRP™ is standardised, leucocyte reduced and easily reproducible. RegenLab specific separating gel technology guarantees minimal variability
- Platelet recovery High platelet quality.
- Viable & functional platelets Full plasma recovery. No loss of plasma growth factors and fibrinogen
- Leucocyte reduced PRP. Depletion of pro-inflammatory granulocytes, leaving mainly lymphocytes and monocytes
- Virtually no red blood cells.
- ATS allows the induction of PRP coagulation in a physiological manner to produce PRP gel, fibrin glue, fibrin clot or suturable fibrin membrane
Technology advantages
The technology ensures consistent PRP preparation with minimal blood, using a safe, closed system and inert separator gel after a quick 5-minute centrifugation at 1500g. It includes pharmaceutical-grade sodium citrate for reversible anticoagulation, is easy to use with minimal training, and streamlines routine clinical practice efficiently.
Biological advantages
RegenLab®'s separator gel ensures reproducible results with over 80% platelet recovery, high platelet quality, full plasma recovery, and minimal red blood cells. It produces leucocyte-reduced PRP, preserving essential growth factors and fibrinogen.
Scientific advantages
The technology's scientific advantages include demonstrated safety and efficacy, with evidence-based outcomes for various therapeutic indications. Supported by over 200 clinical studies, it has a robust foundation of research confirming its effectiveness.
Since 2003, Regen Lab SA has been committed to the development of a unique expertise for the design and manufacturing of high-quality medical devices, intended for cells therapies.